GANIRELIX ACETATE (ganirelix acetate) by Merck & Co. is clinical pharmacology the pulsatile release of gnrh stimulates the synthesis and secretion of luteinizing hormone (lh) and follicle-stimulating hormone (fsh). First approved in 1999.
Drug data last refreshed 9h ago · AI intelligence enriched 1w ago
Ganirelix Acetate is a synthetic gonadotropin-releasing hormone (GnRH) antagonist administered via subcutaneous injection used in assisted reproductive technology (ART) for controlled ovarian hyperstimulation. It works by competitively blocking GnRH receptors on pituitary gonadotrophs, rapidly and reversibly suppressing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion to prevent premature ovulation during fertility treatment cycles.
Product is approaching loss of exclusivity with moderate competitive pressure (30/100), indicating team transitions toward lifecycle management and cost-containment strategies rather than growth expansion.
CLINICAL PHARMACOLOGY The pulsatile release of GnRH stimulates the synthesis and secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). The frequency of LH pulses in the mid and late follicular phase is approximately 1 pulse per hour. These pulses can be detected as transient…
Worked on GANIRELIX ACETATE at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on Ganirelix Acetate offers stable but limited growth opportunity in a specialized fertility market with established protocols and declining patent protection. Career value lies in managed care expertise, specialty pharmacy networks, and defending market position against generic competition rather than new product launches.